Stefanie R. Mullins, Ph.D.
Affiliations: | 2005 | Wayne State University, Detroit, MI, United States |
Area:
Cell Biology, OncologyGoogle:
"Stefanie Mullins"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Bonnie F. Sloane | grad student | 2005 | Wayne State | |
| (The role of proteases during development and malignant progression of the mammary acinar structure in vitro.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kaistha BP, Kar G, Dannhorn A, et al. (2024) Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models. Cancer Biology & Therapy. 25: 2296048 |
| Zanker DJ, Spurling AJ, Brockwell NK, et al. (2020) Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clinical & Translational Immunology. 9: e1177 |
| Mullins SR, Vasilakos JP, Deschler K, et al. (2019) Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Journal For Immunotherapy of Cancer. 7: 244 |
| Mullins SR, Vasilakos J, Deschler K, et al. (2018) Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies Cancer Research. 78: 711-711 |
| Xie B, Tomaszewski MR, Neves A, et al. (2017) Optoacoustic detection of early therapy-induced tumor cell death using a targeted imaging agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Poon E, Mullins S, Watkins A, et al. (2017) The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. Journal For Immunotherapy of Cancer. 5: 63 |
| Leyland R, Watkins A, Mulgrew K, et al. (2017) A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Mullins SR, Vogel K, Vasilakos J, et al. (2017) Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors Cancer Research. 77: 4697-4697 |
| Xie B, Tomaszewski M, Neves AA, et al. (2017) Abstract 2866: Volumetric optoacoustic imaging of tumor cell death using a targeted imaging agent Cancer Research. 77: 2866-2866 |
| Mosely SI, Prime JE, Sainson RC, et al. (2016) Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunology Research |